Industry, Latvia, Markets and Companies

Kirovs Lipmans, chairman of the supervisory council said that the council highly evaluates Hmelnickis' professionalism, knowledge in pharmacy and broad view on the development of pharmaceutical industry, as well as his personal characteristics – determination and goal oriented attitude.

“The rapid growth of Grindex subsidiary Kalceks has given us confidence that Hmelnickis is ready to take the next career step and become the chairman of the board at Grindex. The main tasks for Hmelnickis in his new position will be to expand company’s activities in European Union, the United States of America and South East Asia, as well as to strengthen presence in the CIS countries,” said Lipmans.

Hmelnickis has obtained a PhD in chemistry and a Master’s degree in economics from the University of Latvia and a Master’s degree in business management for quality assurance from Riga Technical University. He has also graduated the Swedish Institute Management Program of Leadership and Sustainable Management.  Hmelnickis is a co-author for a number of scientific publications in analytical research and chromatography.

Janis Romanovskis will continue his work in the board of Grindex.

As reported, Juris Bundulis stepped down as the board chairman of Grindex in late January.

Grindex Group posted EUR 106.564 mln in turnover for the first nine months of 2019, up 4% from the respective period in 2018, while the group’s profit rose 17.6% to EUR 8.906 mln.

Grindex is quoted on the Main List of Nasdaq Riga stock exchange.